ABT-751 (E7010) is primarily used in the field of oncology as an antimitotic agent. It works by inhibiting tubulin polymerization, which is crucial for cell division, thereby preventing the growth of cancer cells. This compound has been investigated in clinical trials for its potential to treat various types of cancers, including pediatric solid tumors, non-small cell lung cancer, and colorectal cancer. Its mechanism of action makes it particularly useful in targeting rapidly dividing cells, a hallmark of cancerous tissues. Additionally, ABT-751 has shown promise in combination therapies, where it is used alongside other chemotherapeutic agents to enhance overall treatment efficacy. Research continues to explore its full potential in improving cancer treatment outcomes.